Observational data have suggested no increased risk of adverse pregnancy outcomes associated with exposure to interferon-beta (IFNB) before or during pregnancy. After the emergence of these data, the European Medicines Agency approved a label change for IFNB in September 2019, stating that use of IFNB during pregnancy may be considered, if clinically needed. However, limited data on pregnancies exposed in the 2nd and 3rd trimesters were observed.
INFORM is a secondary use of data drug utilisation study (DUS) to determine late pregnancy exposure (i.e. during the 2nd and 3rd trimester) to IFNB in Finland and Sweden, which will inform whether the number of exposed pregnancies is adequate to conduct a cohort study on adverse pregnancy outcomes, with a focus on late pregnancy exposure.
The number of pregnancies will be initially reported three years after the revised label implementation (September 2019) and will include data on pregnancies from 1996 in Finland and from 2005 in Sweden up through 31 December 2022. If the number of pregnancies is deemed adequate for conducting the cohort study on adverse pregnancy outcomes, this DUS will be finalised with the drug utilisation data accrued up through 31 December 2022. If the number of pregnancies until 31 December 2022 is deemed inadequate, this study may be continued and the primary and secondary objectives may be examined five years after the revised label implementation, including pregnancies until 31 December 2024.

Start Date20 Mar 2024

Sponsor / Collaborator

Bayer AG

[+3]

NCT04079088 / WithdrawnPhase 2

A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Phase 2 Study to Evaluate the Efficacy and Safety of Oral BIIB061 as Add-On Therapy to Interferon-Beta 1 or Glatiramer Acetate Therapies in Relapsing Multiple Sclerosis

The primary objectives of the study are to evaluate the safety of BIIB061 versus placebo in participants with Relapsing Multiple Sclerosis (RMS), and to evaluate the efficacy of BIIB061 to improve disability outcome versus placebo in participants with RMS.
The secondary objectives of the study are to evaluate the effects of BIIB061 versus placebo on brain magnetic resonance imaging (MRI) markers of remyelination and axon preservation in chronic Multiple Sclerosis lesions and to evaluate the effects of BIIB061 versus placebo on additional measures of improved disability outcome.

Start Date30 Jun 2021

Sponsor / Collaborator

Biogen, Inc.

EUCTR2020-000620-18-FR / Not yet recruitingPhase 2IIT

Human recombinant interferon gamma-1b for the prevention of hospital-acquired pneumonia in critically ill patients: a double-blind, international phase 2, randomized, placebo-controlled trial - the PREV-HAP study - PREV-HAP

Start Date19 Feb 2021

Sponsor / Collaborator

Nantes University Hospital

100 Clinical Results associated with Interferon Beta-1b

100 Translational Medicine associated with Interferon Beta-1b

100 Patents (Medical) associated with Interferon Beta-1b

1,216

Literatures (Medical) associated with Interferon Beta-1b

01 Jul 2024·Neurotherapeutics

Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study

Article

Author: Pesci, Ilaria ; Maimone, Davide ; Maniscalco, Giorgia Teresa ; De Luca, Giovanna ; Amato, Maria Pia ; Paolicelli, Damiano ; Marfia, Girolama ; Bergamaschi, Roberto ; Morra, Vincenzo Brescia ; Solaro, Claudio ; Trojano, Maria ; Ragonese, Paolo ; Lepore, Vito ; Lus, Giacomo ; Zaffaroni, Mauro ; Moiola, Lucia ; Chisari, Clara G ; Granella, Franco ; Cottone, Salvatore ; Totaro, Rocco ; Filippi, Massimo ; Cocco, Eleonora ; Patti, Francesco ; Rovaris, Marco ; Di Sapio, Alessia ; Conte, Antonella ; Bonavita, Simona ; Aguglia, Umberto ; Gasperini, Claudio ; Bertolotto, Antonio ; Cavalla, Paola ; Salemi, Giuseppe ; Gallo, Antonio ; Vianello, Marika

Treatment options for secondary progressive MS (SPMS) are limited, especially considering that the new drugs recently approved are licensed for actively relapsing patients. We aimed to compare the disability progression in a real-world cohort of SPMS patients treated with natalizumab (NTZ) or interferon beta-1b (IFNb-1b). This multicenter retrospective enrolled patients with a diagnosis of SPMS according to 2014 Lublin criteria, who received NTZ or IFNb-1b for at least 48 months between the 1st June 2012 and the 15th May 2018 at 33 Italian MS centers contributing to the Italian MS Registry NTZ or IFNb-1b. Confirmed Expanded Disability Status Scale worsening (CEW) and progression independent of relapse (PIRA) were evaluated. In order to correct for non-randomization, a propensity score matching of the groups was performed. Out of 5206 MS patients identified at the time of data extraction, 421 SPMS patients treated with NTZ (224 [53.2%] females, mean age 45.3 ± 25.4 years) and 353 with IFNb-1b (133 [37.8%] females, mean age 48.5 ± 19.8 years) were enrolled. After applying the matching procedure, 102 patients were retained in the NTZ group and 98 in the IFNb-2b group. The proportion of patients who reached the 48-month 1-point CEW was significantly higher in IFNb-1b compared to NTZ group (58.2% versus 30.4%, p = 0.01). The proportion of patients who developed PIRA at 48 months were significantly higher in IFNb-1b compared to NTZ (72.4% versus 40.2%, p = 0.01). EDSS before treatment initiation and SPMS duration were risk factors for disability progression in terms of PIRA (HR 2.54, 25%CI 1.67-5.7; p = 0.006 and HR 2.04, 25%CI 1.22-3.35; p = 0.01, respectively). Patients treated with IFNb-1b were 1.64 times more to likely to develop PIRA (HR 1.64, 25%CI 1.04-4.87; p = 0.001). Treatment with NTZ in SPMS patients showed more favorable disability outcomes compared to IFNb-1b with beneficial effects over 48 months.

01 Jul 2024·Journal of Neurology

Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial

Article

Author: Wicklein, Eva-Maria ; Barkhof, Frederik ; Montalbán, Xavier ; Freedman, Mark S ; Koelbach, Ralf ; Kappos, Ludwig ; Hartung, Hans-Peter ; MacManus, David G ; Edan, Gilles

AbstractMultiple sclerosis (MS) treatment intervention with immunomodulating therapy at early disease stage improves short term clinical outcomes. The objective of this study is to describe the long-term outcomes and healthcare utilization of patients with clinically isolated syndrome (CIS) included in the Betaferon®/Betaseron® in Newly Emerging MS for Initial Treatment (BENEFIT) randomized, parallel group trial. In BENEFIT patients were assigned to “early” IFNB-1b treatment or placebo (“delayed” treatment). After 2 years or conversion to clinically definite multiple sclerosis (CDMS), all patients were offered IFNB-1b and were reassessed 15 years later. Of 468 patients, 261 (55.8%) were enrolled into BENEFIT 15 (161 [55.1%] from the early, 100 [56.8%] from the delayed treatment arm). In the full BENEFIT analysis set, risk of conversion to CDMS remained lower in the early treatment group ( – 30.5%; hazard ratio 0.695 [95% CI, 0.547–0.883]; p = 0.0029) with a 15.7% lower risk of relapse than in the delayed treatment group (p = 0.1008). Overall, 25 patients (9.6%; 9.9% early, 9.0% delayed) converted to secondary progressive multiple sclerosis. Disability remained low and stable with no significant difference between groups in Expanded Disability Status Scale score or MRI metrics. Paced Auditory Serial Addition Task-3 scores were better in the early treatment group (p = 0.0036 for treatment effect over 15 years). 66.3% of patients were still employed at Year 15 versus 74.7% at baseline. In conclusion, results 15 years from initial randomization support long-term benefits of early treatment with IFNB-1b.

01 Jun 2024·CNS & Neurological Disorders - Drug Targets

The Peripheral Profile of the Chitinase 3-like-1 in Benign Multiple Sclerosis – A Single Centre’s Experience

Article

Author: Balasa, Rodica ; Hutanu, Adina ; Andone, Sebastian ; Barcutean, Laura ; Maier, Smaranda

Background:A limited subgroup of multiple sclerosis (MS) patients present with a longterm disease evolution characterized by a limited disease progression, known as benign MS (BMS). Chitinase 3-like-1 (CHI3L1) levels are sensitive to inflammatory processes and may play a role in the pathogenesis of MS. In this observational, cross-sectional study, we aimed to evaluate the implications of serum CHI3L1 and inflammatory cytokines in BMS patients treated with interferon β-1b for over a decade.Methods:We collected serum samples from 17 BMS patients and 17 healthy controls (HC) to measure serum CHI3L1 levels and a Th17 panel of inflammatory cytokines. Serum levels of CHI3L1 were analysed using the sandwich ELISA method and the Th17 panel was assessed using the multiplex XMap technology on a Flexmap 3D Analyzer.Results:Serum CHI3L1 levels did not differ significantly from HC. We identified a positive correlation between CHI3L1 levels and relapses during treatment.Conclusions:Our findings suggest that there are no differences in serum CHI3L1 levels between BMS patients and HC. However, serum CHI3L1 levels are sensitive to clinical inflammatory activity and may be associated with relapses in BMS patients.

News (Medical) associated with Interferon Beta-1b

18 Sep 2023

·www.biospace.com

Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology

Atriva Therapeutics and Canadian Biocure Technologies, Inc. entered into an exclusive letter agreement for a reverse takeover transaction. Upon successful completion of the transaction, the resulting entity will continue the business of Atriva Therapeutics. Shareholders of Atriva will receive not less than 75% of the securities of the resulting issuer, with the current shareholders of Biocure Technology holding the remainder. The transaction is subject to various terms and conditions, including satisfactory due diligence, successful implementation of a private placement and shareholder approvals. TÜBINGEN, Germany and MUNICH, Germany, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Atriva Therapeutics GmbH (“Atriva”) is pleased to disclose the signing of an exclusive letter agreement, dated September 14, 2023, with Biocure Technology Inc. (“CURE”) (CSE: CURE), based in Vancouver, Canada. This agreement marks a significant step forward in Atriva’s commitment to combating severe RNA virus infections through innovative host-cell-targeting therapies. “We are delighted to have entered into this exclusive letter agreement with Biocure. Our discussions with the Biocure management and board of directors have been exceptionally productive and constructive. We are eager to embark on this journey and combine the strengths of both companies. Together, we aim to address the urgent medical need for safe and effective therapies for patients suffering from severe RNA virus infections. This agreement marks a significant milestone in our commitment to advancing innovative solutions for the benefit of global healthcare,” said Christian Pangratz, Chief Executive Officer of Atriva. “This letter agreement underscores our commitment to leverage this transaction with CURE as an attractive growth option for Atriva and its stakeholders. We are enthusiastic about the prospect of our companies joining forces and continuing to contribute to improving pandemic preparedness on an extended international scale,” stated Ulrich Dauer, PhD, Chairman of the Advisory Board of Atriva. Highlights of the Transaction: Upon transaction completion, Atriva shareholders and concurrent financing subscribers will collectively hold not less than 75% of the securities of the resulting issuer. Current CURE shareholders will retain a maximum of 25% on a fully diluted basis. The letter agreement stipulates no advances from CURE to Atriva. Atriva will provide CURE with an exclusivity fee of CA$15,000 per month for a minimum of three months. Additionally, a finder's fee of US$2,000,000 is payable through the issuance of CURE shares, with pricing to be determined, aligning with concurrent private placement terms. Transaction Conditions: The completion of the Transaction is contingent upon various terms and conditions, including the successful completion of due diligence, the execution of a definitive agreement by November 30, 2023, (inclusive of typical transaction elements), and the successful completion of a private placement by Atriva or CURE to raise gross proceeds of at least US$15,000,000. Additionally, approval from both companies' shareholders and the endorsement of the CSE and other relevant regulatory authorities are essential prerequisites for finalization. For additional information on this transaction, please visit . About Atriva Therapeutics Atriva Therapeutics’ mission is to develop an antiviral therapy platform against severe respiratory and systemic diseases with a high unmet medical need induced by RNA viruses, e.g., influenza and COVID-19. The clinical-stage biopharmaceutical company is pioneering the development of host-targeting antiviral therapies, making development of viral resistance unlikely, and thereby significantly contributing to pandemic preparedness. The Atriva lead product zapnometinib (ATR-002) is a first-in-class, host-targeting agent that aims to inhibit viral replication and to favorably modulate the body’s immune response to RNA viruses. Atriva Therapeutics was founded in 2015 in Tübingen by a team of leading scientists in viral research and seasoned industry experts and is based with its administrative/operations office in Martinsried (near Munich), Germany. For further information, please visit and follow us on LinkedIn and X (formerly Twitter). About Biocure Biocure owns approximately 45% stakes of BiocurePharm in Korea who is a leading biotech company developing its CAR-T cell therapy for leukemia, lung, breast and pancreatic cancer. BiocurePharm is in the process of pre-clinical trials of three major biosimilar products in South Korea, including Interferon Beta 1b, PEG- Filgrastim as well as Ranibizumab. Interferon Beta 1b is used for treating relapsing forms of multiple sclerosis (“MS”). Filgrastim is used to treat neutropenia, a lack of certain white blood cells caused by bone marrow transplants, chemotherapy, and other conditions. Ranibizumab is used for treating macular degeneration. It is also used to treat a type of eye problem known as macular edema, as well as certain eye problems caused by diabetes. Contact: Atriva Therapeutics GmbH Christian Pangratz, CEO Phone: +49 69 9999 162 10 pangratz@atriva-therapeutics.com

ImmunotherapyCell Therapy

02 Aug 2022

·endpts.com

Granfluencers and boomfluencers: Is the hipster oldster social media trend moving to pharma?

Cathy Chester’s latest Instagram post is about her experience being pregnant while having multiple sclerosis — in 1992. That was six years after her initial diagnosis and one year before Betaseron became the first FDA-approved drug to treat the underlying disease in relapsing-remitting MS. Chester, now 63, writes about how a few years before she became pregnant, when she was considering getting married, she drove more than 90 minutes to hear a specialist talk about MS and pregnancy. Because the internet was still emerging then, and modern smartphones were only a twinkle in Apple’s eye, she couldn’t just “look it up.” And her doctors back then weren’t as open to listening to patients’ personal issues as they are today.

10 Jun 2021

·www.globenewswire.com

Multiple Sclerosis Drugs Market to Reach USD 41.99 Billion by 2028; Rising Support from Governments and Launch of Awareness Initiatives to Aid Growth: Fortune Business Insights™

Pune, India, June 10, 2021 (GLOBE NEWSWIRE) -- The global multiple sclerosis drugs market size is set to gain traction as many leading pharmaceutical companies are conducting clinical trials to discover innovative and effective therapies for the treatment of this immune disorder. For instance, in December 2020, Adamas Pharmaceuticals, Inc. declared the results of its phase 3 clinical trials on ADS-5102, for the treatment of multiple sclerosis (MS) patients. This information is given by Fortune Business Insights™ in a published report, titled, “Multiple Sclerosis Drugs Market, 2021-2028.” As per the report, the market size was USD 26.05 billion in 2020 and is projected to reach USD 41.99 billion by 2028, exhibiting a CAGR of 6.3 % during the forecast period. COVID-19 Pandemic: Disruptions in Supply Chain and Production Delays to Hinder Growth The outbreak of the COVID-19 pandemic has severely affected the multiple sclerosis drugs market growth as it has caused some disruption in the supply chain of several major players operating in the multiple sclerosis drugs industry. For example, Biogen reported that one of its major drugs named TECFIDERA used for the treatment of multiple sclerosis witnessed a decline of 13% in 2020 as compared to the previous year. This decline was seen as a DMT based approach for the treatment of MS that has an adverse effect on COVID-19 patients. These factors are expected to moderately impact the market growth. Request a Sample Copy of Research Report: Industry Developments August 2020 - Novartis launched its U.S. Food and Drug Administration (FDA) has approved subcutaneous injection Kesimpta (ofatumumab), for the treatment of relapsing forms of multiple sclerosis (RMS). January 2020 - Bristol Myers Squibb launched Zeposia. This drug is one of the economical drugs available in the market for MS patients. Report Coverage- The report aims to analyze the multiple sclerosis drugs industry by considering contributions, prospects, and growth trends. It presents detailed profiles of every key player operating in the market to analyze their core competencies in each segment. Apart from that, it ensures to help our clients better understand the competitive developments, such as mergers & acquisitions, new product launches, joint ventures, and collaborations. To get to know more about the short-term and long-term impact of COVID-19 on this market, please visit: Immunomodulators to Dominate the Market Owing to New Drug Launches By drug class, the market is divided into immunomodulators, immunosuppressants, interferons, and others. Out of these, immunomodulators dominated the market in 2020 owing to new drug launches such as Mayzent. On the other hand, immunosuppressants are also expected to see a substantial rise as the drug MAVENCLAD is characterized with long-term efficacy for the treatment of MS. Proactive Measures Taken by Governments to Strengthen the Market Growth As the prevalence of MS is increasing at an alarming rate, governments are aiding the market by campaigning about different treatment options available. In June 2018, for instance, the National Institute of Health and Care Excellence (NICE) announced recommendations for the use of beta interferons such as Avonex, Betaferon, Extavia, Rebif. These steps taken by government agencies will fuel the market in the upcoming years. Despite government interference, the cost of drugs for multiple sclerosis remains a major challenge for the growth of the market. From 2013 to 2018, the price was increased by more than US$ 20,000. Thus, increased prices of the drugs will add to the economic burden owing to the rise of out-of-pocket expenses. Quick Buy Multiple Sclerosis Drugs Market Research Report: List of Key Players Covered in the Multiple Sclerosis Drugs Market Report: Have Any Query? Ask Our Experts: Detailed Table of Content: TOC Continued…..!!!! Get your Customized Research Report: Have a Look at Related Reports: Telehealth Market Size, Share and Global Trend By Type (Products, Services), By Application (Telemedicine, Patient Monitoring, Continuous Medical Education, Others), By Modality (Store-and-forward (Asynchronous), Real-time (Synchronous), Remote Patient Monitoring), By End User (Healthcare Facilities, Homecare, Others), and Geography Forecast till 2026 Contraceptive Drugs Market Size, Share and Global Trend By Product Type (Oral, Injectable, Patches), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Clinics, Online Channel, Public Channel & NGOs) and Geography Forecast till 2025 Hereditary Angioedema Treatment Market Size, Share and Global Trend by Drug Class (C-1 Esterase Inhibitors, Bradykynin Receptor Antagonist, Kallikrein Inhibitors), Application (Prophylaxis, Treatment), Route of Administration (IV, Subcutaneous), Distribution Channel (Hospital Pharmacy, Retail Pharmacy) and Geography Forecast till 2025 Thrombin Market Size, Share and Global Trend By Product (Bovine Thrombin, Human Thrombin, Recombinant Thrombin), By Dosage Form (Powder Form, Solution Form), By End user (Hospitals, Diagnostics Centers & Clinics, Academics and Research Institutes), and Geography Forecast till 2025 About Us: Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in. Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data. At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges. Contact Us: Fortune Business Insights™ Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India. Phone:US :+1 424 253 0390UK : +44 2071 939123APAC : +91 744 740 1245Email: sales@fortunebusinessinsights.comFortune Business Insights™LinkedIn | Twitter | Blogs Press:

AcquisitionCollaborate

100 Deals associated with Interferon Beta-1b

External Link

KEGG	Wiki	ATC	Drug Bank
D00746	Interferon Beta-1b	L03AB08	DB00068

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Multiple Sclerosis, Relapsing-Remitting	IS	Bayer AG	30 Nov 1995
Multiple Sclerosis, Relapsing-Remitting	EU	Bayer AG	30 Nov 1995
Multiple Sclerosis, Relapsing-Remitting	LI	Bayer AG	30 Nov 1995
Multiple Sclerosis, Relapsing-Remitting	NO	Bayer AG	30 Nov 1995
Multiple Sclerosis, Secondary Progressive	NO	Bayer AG	30 Nov 1995
Multiple Sclerosis, Secondary Progressive	EU	Bayer AG	30 Nov 1995
Multiple Sclerosis, Secondary Progressive	IS	Bayer AG	30 Nov 1995
Multiple Sclerosis, Secondary Progressive	LI	Bayer AG	30 Nov 1995
Multiple Sclerosis	US	Bayer HealthCare Pharmaceuticals, Inc.	23 Jul 1993

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple Sclerosis	Phase 3	IL	Bayer AG	01 Aug 2002
Multiple Sclerosis	Phase 3	BE	Bayer AG	01 Aug 2002
Multiple Sclerosis	Phase 3	IT	Bayer AG	01 Aug 2002
Multiple Sclerosis	Phase 3	DK	Bayer AG	01 Aug 2002
Multiple Sclerosis	Phase 3	HU	Bayer AG	01 Aug 2002
Multiple Sclerosis	Phase 3	NL	Bayer AG	01 Aug 2002
Multiple Sclerosis	Phase 3	SI	Bayer AG	01 Aug 2002
Multiple Sclerosis	Phase 3	FR	Bayer AG	01 Aug 2002
Acquired Immunodeficiency Syndrome	Phase 3	US	Bayer AG	31 Aug 2001
AIDS-Related Complex	Phase 3	US	Bayer AG	31 Aug 2001

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ECTRIMS2022	Not Applicable	Multiple Sclerosis, Relapsing-Remitting	140	Actoferon®	trjjuqypyy(jozzfetsso) = ktzqyozfoi akmqrawwmm (shwzkasivf ) View more	Positive	12 Oct 2022
ECTRIMS2022	Not Applicable	Multiple Sclerosis, Relapsing-Remitting	140	Betaferon®	trjjuqypyy(jozzfetsso) = ymlrnsarnr akmqrawwmm (shwzkasivf ) View more	Positive	12 Oct 2022
Pubmed	Phase 2	COVID-19	-	Interferon beta-1b + Remdesivir	nxkqlayxal(zrpyjmyekm) = wpqqbnujlb ohlkkeuqlp (hierufsksj ) View more	Positive	28 Jun 2022
Pubmed	Phase 2	COVID-19	-	Remdesivir	nxkqlayxal(zrpyjmyekm) = zikdouxluq ohlkkeuqlp (hierufsksj ) View more	Positive	28 Jun 2022
NCT00176592 (BECOME, CTgov)	Phase 4	Multiple Sclerosis	75	Betaseron (Betaseron)	hnxyetxisw(cghnqmbizm) = njsorcwtwm oceqwgiuxb (skxqtrkazf, kjgwblrtwo - nkxuqhdesx) View more	-	16 Nov 2021
NCT00176592 (BECOME, CTgov)	Phase 4	Multiple Sclerosis	75	Copaxone (Copaxone)	hnxyetxisw(cghnqmbizm) = shrzeldhgp oceqwgiuxb (skxqtrkazf, utnwqfwofp - jyckapquyn) View more	-	16 Nov 2021
ECTRIMS2020	Not Applicable	COVID-19 SARS-CoV-2	109	IFN β-1b	(heptvqfuyh) = jymhpjgqcq gegubyacru (omucgqgrvj ) View more	-	07 Dec 2020
NCT03134573 (Pubmed \| J Med Internet Res)	Not Applicable	Multiple Sclerosis	96	Interferon Beta-1b (Patients using myBETAapp)	llbgjdijwa(xgcwhonmzr) = tfoytmbszp xksaaryfpr (yihqwygrgd ) View more	-	29 Jul 2019
AAN2019	Not Applicable	Pregnancy	2,571	Interferon beta-1b	fkpwvpbvxj(wmqrnjgvtx) = gqsbkfkxqm frgfndolyv (jixskzbkrp ) View more	-	09 Apr 2019
ACTRIMS2018	Not Applicable	-	-	Interferon beta-1b	(ffsfmusaxm) = vjjpdbkphi iqyqduzzvs (rvdgeospfs ) View more	-	14 Mar 2018
BETAPAEDIC (AAN2017)	Not Applicable	Multiple Sclerosis, Relapsing-Remitting	68	Interferon beta-1b	(bmkiytedej) = The most frequent drug-related AEs were flu-like symptoms (46.3%), headache (19.4%), injection site reactions (16.4%), and abnormal liver function tests (11.9%) ompkdzpyqh (vsgslczdlx )	Positive	18 Apr 2017
AAN2017	Not Applicable	-	-	Interferon beta-1b	xjqjiawdzy(kasgukvwyq) = sqbsyklogy fgksfpybqg (vndrqjkofz ) View more	-	18 Apr 2017
NCT00902135 (Pubmed \| Adv Ther)	Not Applicable	Multiple Sclerosis	702	Interferon Beta-1b (PDA with diary function)	cfoptqsgut(jorxrvznkz) = mntyybhmht ugkhxkdjch (trurpmxjak ) View more	-	01 May 2016
NCT00902135 (Pubmed \| Adv Ther)	Not Applicable	Multiple Sclerosis	702	Interferon Beta-1b (Paper patient diary)	zhyqlyfpis(leekymhxat) = gczeafarve twdmrbbevl (zyyephyomq )	-	01 May 2016

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis